Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy

Neurodegenerative Diseases

Volumn 11, Issue 4, 2013, Pages 165-181

  Selenica, Maj Linda B ^a   Brownlow, Milene ^a   Jimenez, Jeffy P ^a   Lee, Daniel C ^c   Pena, Gabriela ^a   Dickey, Chad A ^b   Gordon, Marcia N ^a   Morgan, Dave ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Amyloid; Glycogen synthase kinase 3 ; Inflammation; Microglia; Microosmotic pump; Phosphorylation; Tau

Indexed keywords

AMYLOID BETA PROTEIN; CD45 ANTIGEN; CD68 ANTIGEN; EPITOPE; GLYCOGEN SYNTHASE KINASE 3; OLIGOMER; TAU PROTEIN; AMYLOID BETA PROTEIN[1-42]; CD11B ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; HIPPOCAMPUS; IMPLANTATION; MICROGLIA; MINIPUMP; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TAUOPATHY; CELL ACTIVATION; COMPARATIVE STUDY; CORPUS STRIATUM; DISEASE EXACERBATION; ENTORHINAL CORTEX; FRONTAL CORTEX; GLIOSIS; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOLECULAR WEIGHT; PAIRED HELICAL FILAMENT; PERIKARYON; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PYRAMIDAL NERVE CELL; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; ANIMALS; ANTIGENS, CD; ANTIGENS, CD45; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; MICE; MICE, TRANSGENIC; MICROGLIA; NEURONS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; TAU PROTEINS; TAUOPATHIES;

EID: 84876406070     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000337230     Document Type: Article

References (53)

1. Trojanowski JQ, Schmidt ML, Shin RW, Bramblett GT, Rao D, Lee VM: Altered tau and neurofilament proteins in neuro-degenerative diseases: diagnostic implications for Alzheimer's disease and Lewy body dementias. Brain Pathol 1993; 3: 45-54.
2. Li B, Chohan MO, Grundke-Iqbal I, Iqbal K: Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau. Acta Neuropathol 2007; 113: 501-511.
3. Konzack S, Thies E, Marx A, Mandelkow EM, Mandelkow E: Swimming against the tide: mobility of the microtubule-associated protein tau in neurons. J Neurosci 2007; 27: 9916-9927.
4. LaPointe NE, Morfini G, Pigino G, Gaisina IN, Kozikowski AP, Binder LI, Brady ST: The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J Neurosci Res 2009; 87: 440-451.
5. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, et al: Association of missense and 5-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998; 393: 702-705.
6. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, Andreadis A, Wiederholt WC, et al: Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol 1998; 43: 815-825.
7. Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, et al: Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 2005; 25: 10637-10647.
8. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, et al: Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005; 309: 476-481.
9. Bolmont T, Clavaguera F, Meyer-Luehmann M, Herzig MC, Radde R, Staufenbiel M, Lewis J, Hutton M, et al: Induction of tau pathology by intracerebral infusion of amyloid-beta-containing brain extract and by amyloidbeta deposition in APP x Tau transgenic mice. Am J Pathol 2007; 171: 2012-2020.
10. Gotz J, Chen F, van Dorpe J, Nitsch RM: Formation of neurofibrillary tangles in P301l tau transgenic mice induced by A-42 fibrils. Science 2001; 293: 1491-1495.
11. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM: Temporal profile of amyloid-beta (A-) oligomerization in an in vivo model of Alzheimer disease. A link between A-and tau pathology. J Biol Chem 2006; 281: 1599-1604.
12. Selkoe DJ: Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-791.
13. O'Nuallain B, Klyubin I, Mc Donald JM, Foster JS, Welzel A, Barry A, Dykoski RK, Cleary JP, et al: A monoclonal antibody against synthetic A-dimer assemblies neutralizes brain-derived synaptic plasticitydisrupting A-. J Neurochem 2011; 119: 189-201.
14. Barry AE, Klyubin I, Mc Donald JM, Mably AJ, Farrell MA, Scott M, Walsh DM, Rowan MJ: Alzheimer's disease brain-derived amyloid-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J Neurosci 2011; 31: 7259-7263.
15. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL: Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 2003; 100: 10417-10422.
16. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH: A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440: 352-357.
17. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A: Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 2002; 99: 6364-6369.
18. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, et al: Amyloid-/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 2011; 31: 700-711.
19. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, et al: Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007; 316: 750-754.
20. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, et al: Dendritic function of tau mediates amyloidbeta toxicity in Alzheimer's disease mouse models. Cell 2010; 142: 387-397.
21. Stine WB Jr, Dahlgren KN, Krafft GA, LaDu MJ: In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 2003; 278: 11612-11622.
22. Selenica ML, Wang X, Ostergaard-Pedersen L, Westlind-Danielsson A, Grubb A: Cystatin C reduces the in vitro formation of soluble A-1-42 oligomers and protofibrils. Scand J Clin Lab Invest 2007; 67: 179-190.
23. Carty N, Lee D, Dickey C, Ceballos-Diaz C, Jansen-West K, Golde TE, Gordon MN, Morgan D, et al: Convection-enhanced delivery and systemic mannitol increase gene product distribution of AAV vectors 5, 8, and increase gene product in the adult mouse brain. J Neurosci Methods 2010; 194: 144-153.
24. Craft JM, Watterson DM, Van Eldik LJ: Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration. Glia 2006; 53: 484-490.
25. Gordon MN, Holcomb LA, Jantzen PT, Di-Carlo G, Wilcock D, Boyett KW, Connor K, Melachrino J, et al: Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 2002; 173: 183-195.
26. LaFerla FM, Oddo S: Alzheimer's disease: A-, tau and synaptic dysfunction. Trends Mol Med 2005; 11: 170-176.
27. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, et al: Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 2001; 293: 1487-1491.
28. Selenica ML, Jensen HS, Larsen AK, Pedersen ML, Helboe L, Leist M, Lotharius J: Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br J Pharmacol 2007; 152: 959-979.
29. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM: Abnormal tau phosphorylation at Ser 396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993; 10: 1089-1099.
30. Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, Blair L, Gordon MN, et al: LPS-induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflammation 2010; 7: 56.
31. Kantarci K, Boeve BF, Wszolek ZK, Rademakers R, Whitwell JL, Baker MJ, Senjem ML, Samikoglu AR, et al: MRS in presymptomatic MAPT mutation carriers: a potential biomarker for tau-mediated pathology. Neurology 2010; 75: 771-778.
32. Braak H, Thal DR, Ghebremedhin E, Del Tredici K: Stages of the pathologic process in Alzheimer disease: age categories from 1 to years. J Neuropathol Exp Neurol 2011; 70: 960-969.
33. Hutton M: Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms. Neurology 2001; 56(suppl 4):S21-S25.
34. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
35. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BA: Aging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat Med 1998; 4: 827-331.
36. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM: A-immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43: 321-332.
37. Wilcock DM, Gharkholonarehe N, Van Nostrand DE, Davis J, Vitek MP, Colton CA: Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J Neurosci 2009; 29: 7957-7965.
38. Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, et al: Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 2010; 68: 1067-1081.
39. Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O'Hare E, Esler WP, Maggio JE, et al: Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 1998; 18: 2161-2173.
40. Holcomb LA, Gordon MN, Benkovic SA, Morgan DG: A beta and perlecan in rat brain: glial activation, gradual clearance and limited neurotoxicity. Mech Ageing Dev 2000; 112: 135-152.
41. Dickey C, Kraft C, Jinwal U, Koren J, Johnson A, Anderson L, Lebson L, Lee D, et al: Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy. Am J Pathol 2009; 174: 228-238.
42. Carty NC, Wilcock DM, Rosenthal A, Grimm J, Pons J, Ronan V, Gottschall PE, Gordon MN, et al: Intracranial administration of deglycosylated C-terminal-specific anti-A-antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J Neuroinflammation 2006; 3: 11.
43. DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D: Intrahippocampal LPS injections reduce A-load in APP+PS1 transgenic mice. Neurobiol Aging 2001; 22: 1007-1012.
44. Herber DL, Mercer M, Roth LM, Symmonds K, Maloney J, Wilson N, Freeman MJ, Morgan D, et al: Microglial activation is required for A-clearance after intracranial injection of lipopolysaccharide in APP transgenic mice. J Neuroimmune Pharmacol 2007; 2: 222-231.
45. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D: Intracranially administered anti-A-antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 2003; 23: 3745-3751.
46. Zempel H, Thies E, Mandelkow E, Mandelkow EM: A-oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci 2010; 30: 11938-11950.
47. Asuni AA, Hooper C, Reynolds CH, Lovestone S, Anderton BH, Killick R: GSK3-exhibits-catenin and tau directed kinase activities that are modulated by Wnt. Eur J Neurosci 2006; 24: 3387-3392.
48. Engel T, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J, Hernandez F: Cooexpression of FTDP-17 tau and GSK-3-in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging 2006; 27: 1258-1268.
49. Leroy K, Yilmaz Z, Brion JP: Increased level of active GSK-3-in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 2007; 33: 43-55.
50. De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco VT, Lacor PN, Bigio EH, Jerecic J, et al: Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging 2008; 29: 1334-1347.
51. Ma QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ, Glabe CG, Teter B, et al: Antibodies against beta-amyloid reduce A-oligomers, glycogen synthase kinase-activation and tau phosphorylation in vivo and in vitro. J Neurosci Res 2006; 83: 374-384.
52. Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI: Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1994; 57: 419-425.
53. Ransohoff RM, Perry VH: Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009; 27: 119-145.